ADVANZ PHARMA strengthens its specialty pharmaceuticals portfolio by acquiring Tostran® from Kyowa Kirin

ADVANZ PHARMA strengthens its specialty pharmaceuticals portfolio by acquiring Tostran^® from Kyowa Kirin

• ADVANZ PHARMA has signed an agreement to acquire the global rights to Tostran^®, a testosterone gel for treating men with hypogonadism, from Kyowa Kirin.
• Acquisition will further strengthen ADVANZ PHARMA’s specialty pharmaceuticals portfolio and support its growth ambition in Europe.

LONDON, April 25, 2023 - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, has signed an agreement with Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) to acquire the global rights to Tostran^®. Completion of the acquisition is expected to take place during Q2 2023.

Tostran^® is a testosterone gel used for treating men with hypogonadism, who display associated clinical signs and symptoms of testosterone deficiency, such as fatigue, depression, decreased libido, and loss of muscle mass.

The acquisition will further strengthen ADVANZ PHARMA's specialty pharmaceuticals portfolio and support its growth ambition in Europe. Tostran^® is currently marketed across Europe, including the UK, Italy, Spain, Germany, France, the Nordics, and the Netherlands, as well as in the US. ADVANZ PHARMA will leverage its existing specialty pharmaceutical infrastructure to ensure continued patient access to Tostran^®.